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Erythropoietin should be part of congestive heart failure man-
agement.
Background. Up to 64% of patients referred to nephrolo-
gists with chronic kidney insufficiency (CKI) have evidence of
congestive heart failure (CHF), and most of these patients are
also anemic. We have called this triad of anemia, CKI, and
CHF the cardio renal anemia (CRA) syndrome. The 3 compo-
nents of this syndrome form a vicious circle, with each one
capable of causing or worsening the other 2. Anemia is found
in one-third to one-half of CHF patients and can either cause
or worsen the CHF, and can increase the mortality, hospitaliza-
tion, and malnutrition in this condition. Anemia is also associ-
ated with a worsening of renal function in CHF and CKI,
causing a more rapid progression to dialysis than is found
in those without anemia. Uncontrolled CHF can cause rapid
deterioration of renal function and may also cause anemia.
Chronic kidney insufficiency can cause anemia and worsen
the CHF.
Methods. Aggressive therapy of CHF with all the accepted
CHF medications in the accepted doses will often fail to im-
prove the CHF if anemia is also present but is not corrected.
However, when the anemia was corrected with subcutaneous
erythropoietin and, in some cases, with intravenous iron, the
cardiac and patient function and quality of life improved, the
need for hospitalization and for high-dose oral and intravenous
diuretics was strikingly reduced, and renal function, which had
previously been deteriorating, stabilized.
Results. Nephrologists should carefully assess the cardiac
status of all CKI patients, including routinely getting an echo-
cardiogram and possibly measuring B-type natriuretic peptide.
Where CHF is present, the indicated CHF agents in the indi-
cated doses should be used.
Conclusion. Studies show that most cardiologists and inter-
nists do not recognize, investigate, or treat the anemia fre-
quently seen in their CHF patients. In our experience coopera-
tion between nephrologists and these specialists has increased
their awareness about anemia, resulting in its earlier correction,
and thus preventing the deterioration of the CHF, the CKI,
and the anemia itself.
Despite the fact that there have been many advances
in the therapy of congestive heart failure (CHF), a recent
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Framingham Study showed that the age-corrected life
expectancy for males has hardly changed in 50 years,
having fallen from 30% in 1950 to only 28% in 1999 [1].
Part of this unfortunate state may be due to the striking
underutilization of medications proven to be useful in
CHF, especially beta blockers and angiotensin-convert-
ing enzyme (ACE) inhibitors. In a recent large study of
treatment of CHF in the community it was found that
only 20% of cases were receiving both medications [2].
But there may be other reasons for the persistent high
mortality. One may be the high prevalence of untreated
anemia in CHF. We propose that CHF and anemia form
a vicious circle with chronic kidney insufficiency (CKI).
We have called this triad the Cardio Renal Anemia
(CRA) syndrome [3, 4] (Fig. 1).
We define anemia as a hemoglobin (Hb) of 12 g/dL,
CKI as a creatinine clearance of 60 mL/min/1.73/m2,
and CHF as a condition diagnosed by accepted clinical,
radiologic, and laboratory criteria.
In this vicious circle one can see that anemia can cause
CHF, CHF can cause anemia, anemia can cause CKI,
CKI can cause anemia, CHF can cause CKI, and CKI
can cause CHF.
In the last few years we have found a large number
of CHF patients with CKI who, despite treatment with
maximally tolerated doses of all the recommended CHF
medications, have not improved clinically [3–6]. The one
thing they had in common was a Hb of 12 g/dL. When
this was corrected with subcutaneous erythropoietin
(EPO) and intravenous iron (Fe Sucrose; Venofer; Vifor
International, St. Gallen, Switzerland) the CHF im-
proved and the renal function stabilized or improved.
We believe that this syndrome is a very common cause
of progressive CHF and CKI and that, unless both the
CHF and the anemia are adequately treated, all 3 will
progress with time.
Is anemia recognized as a problem in CHF
by specialists?
The role of anemia in CHF has generally been ignored
by cardiologists. It is not mentioned at all in 2 recent
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Fig. 1. The Cardio Renal Anemia Syndrome. CHF, congestive heart
failure; CKI, chronic kidney insufficiency.
United States guidelines on the diagnosis and treatment
of CHF [7, 8]. The attitude of physicians treating CHF
patients to anemia (as defined as a Hb of 12 g/dL in
men and11 g/dL in females) has recently been studied
in the United States [9]. Of 2011 consecutive patients
with chronic stable heart failure seen at tertiary cardiol-
ogy and internal medicine clinics, anemia appeared in
29% of cases during the follow-up period and, once it
appeared, persisted in 93.4% of cases. When it was pres-
ent, it was included among the patients’ diagnoses, how-
ever, in only 11% of cases seen by internists and in
only 4% of cases seen by cardiologists. A diagnostic
evaluation was performed in only 6% of all these anemic
CHF patients and only 10% received medical therapy
for it. As stated by the investigators, anemia was under-
recognized, under-diagnosed, and under-treated.
How common is anemia in CHF?
In the 142 cases of CHF we followed in our outpatient
CHF clinic [5], we found that 55.6% of these ambulatory
CHF patients were anemic, as defined by a hemoglobin
(Hb) of less than 12 g/dL. In another study of 338 hospi-
talized patients with a primary diagnosis of CHF we
found that the admission Hb was 12 g/dL in 52.4%
[10]. As we recently summarized [11], while some investi-
gators have reported a similar prevalence of anemia of
about 40 to 60% [12–15], others have reported a preva-
lence of only about 15 to 30% [16–19]. In general one
third to one half of CHF patients are anemic [11]. The
reasons for the differences in prevalence in the various
studies are probably the different definitions of anemia
used, and the different nature of the populations studied.
The prevalence rates of anemia have been higher in
older than younger patients, higher in those hospitalized
than in those seen in outpatient departments, and high-
er in those with more severe CHF and more severe
CKI [11].
Anemia and the severity of CHF
We found that the worse the CHF, the more prevalent
and severe the anemia, such that 9.1% of cases of mild
CHF [New York Heart Association (NYHA) I] were
anemic, the mean Hb of this group being 13.7 g/dL,
while in contrast, in severe CHF, NYHA IV, 79.1% were
anemic and the mean Hb had fallen to 10.9 g/dL [5].This
inverse relationship between severity of CHF and Hb
level has also been found by others [12, 17, 19, 20].
Indeed, in 13 studies in which this relationship was exam-
ined, it was confirmed in 12 of them [11].
Anemia and hospitalization for CHF
A relationship between severity of anemia and num-
ber of hospitalizations and rehospitalizations has been
found in several studies [14, 21]. Of 5 studies that exam-
ined this, all of them showed this relationship [11]. This
could be very important, since CHF is a very common
cause of hospitalization in those aged 65 and older [22].
In addition, many of these are hospitalized again and
again because of the CHF [22]. In fact, the major cost
of the care of CHF patients is hospitalization costs [22]. A
similar relationship between anemia and hospitalizations
has been seen in chronic kidney insufficiency (CKI)
[23, 24] and in patients on dialysis [25].
Anemia and mortality in CHF and coronary heart
disease (CHD)
A relationship between severity of anemia and mortal-
ity has also been found in CHF [13–15, 18–20], that being
the more severe the anemia, the greater the mortality.
This relationship was found in 14 of 15 studies in which
it was examined [11]. The anemia increased the mortality
50 to 100% independent of other factors [11]. The pres-
ence of CKI is additive and doubles the mortality [13, 20].
In patients with coronary heart disease (CHD), long-
term studies have also found that anemia is associated
with an increase in mortality of about 400% [26, 27] that
is independent of renal function [27], although anemia
and CKI have an additive effect on the mortality [27].
Is CKI common in CHF and what is its significance?
In our study of 142 cases of CHF mentioned above
[5], 58 (40.8%) had CKI as defined as a serum creatinine
1.5 mg/dL. We also noted that the serum creatinine
rose steadily as the CHF became more severe. The high
prevalence of CKI in CHF, and the increase in its preva-
lence and severity with increasing severity of CHF have
also been noted by others [28, 29]. Chronic kidney insuf-
ficiency has also been found to be an independent risk
factor for mortality in CHF [28, 29]. The myocardium is
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directly damaged in uremia [30]. There are probably
many reasons for this, including anemia, hypertension,
fluid retention, elevated homocysteine levels, hyperpara-
thyroidism, and oxidative stress [30, 31].
Is anemia more common in CHF patients who also
have CKI?
In a recent study of 338 patients hospitalized with
CHF [10] we found that 161 (47.6%) had a serum creati-
nine 1.5 mg/dL, and 177 (52.4%) had a serum creati-
nine 1.5 mg/dL. One hundred fourteen (70.8%) of the
former were anemic compared to only 63 (35.6%) of the
latter. Thus, anemia was twice as common in those CHF
patients with CKI as those without it.
Can anemia itself cause CKI?
While the CKI may be contributing to the production
of anemia, the opposite may also be true. It is possible
that anemia itself is contributing to the severity and pro-
gression of the CKI. In the RENAAL study, a random-
ized double-blind clinical trial that studied 1513 patients
with type 2 diabetes and nephropathy over a mean of
3.4 years [32], patients were administered either losartan
or placebo. By multivariate analysis the hazard ratio for
doubling the serum creatinine or developing end-stage
renal disease (ESRD) for Hb (g/dL) was 0.89 (CI, 0.84–
0.95). This suggests that a normal Hb is protective against
progressive CKI. This possible protective effect of Hb
on renal function has been found in other studies of CKI
as well [33].
CHF as a cause of progression of CKI
Congestive heart failure has been found in up to 64%
of patients referred to nephrologists with moderate to
severe CKI [34]. That CHF itself may be an important
contributor to the production of CKI is suggested by
a study of 11,192 patients with essential hypertension
followed over 15 years [35]. One of the strongest pre-
dictive risk factors for reaching ESRD was the advent
of CHF. It is known that the glomerular filtration rate
falls at a rate of about 1 mL/min/month in patients who
develop CHF after a myocardial infarction [36]. Studies
have also shown that it may be possible to prevent this
deterioration of renal function with a combination of
beta blockers and ACE inhibitors [37] suggesting that
good treatment of CHF can stabilize CKI. This is consis-
tent with a study that showed that CKI patients with
cardiovascular disease (CVD) progress to ESRD more
rapidly than those without CVD [38]. The probable
mechanism whereby CHF causes progressive CKI is the
persistent renal vasoconstriction resulting in renal hyp-
oxia, which can lead to renal cell death and fibrosis [39].
The direct toxic effects of angiotensin, aldosterone, and
noradrenaline on renal tissue contribute to this destruc-
tion [39].
Can CHF itself cause anemia?
The main cause of the anemia in CHF is most likely the
CKI produced by the prolonged renal vasoconstriction
leading to prolonged renal ischemia. Renal damage
causes reduced production of erythropoietin (EPO) in
the kidneys [40]. However, as mentioned above, many
anemic CHF patients have a normal serum creatinine,
so that it is unlikely that CKI is the entire explanation
for the anemia seen in CHF. Indeed, studies in animals
have shown that CHF itself may cause anemia [41]. The
damaged heart secretes cytokines such as tumor necrosis
factor alpha (TNF) [41, 42], which can cause anemia
in three ways [43]: by reducing EPO production in the
kidneys; by interfering with EPO activity at the level of
the bone marrow; and by inhibiting the release of iron
from the reticulo-endothelial system so that it cannot
get to the bone marrow to be utilized in Hb production.
Studies in CHF have shown that the higher the blood
levels of TNF, the lower the Hb [44]. We recently stud-
ied the individual contribution of CHF and CKI to ane-
mia in 3 groups of patients: (1) Group I, patients with
CHF without CKI (serum creatinine 1.5 mg/dL); (2)
Group II, patients with mild CKI (serum creatinine 1.5
to 2.5 mg/dL); and (3) Group III, patients with both
CHF and mild CKI (M Blum et al, submitted for publica-
tion). The percentage with anemia (Hb 12 g/dL) was
32.1%, 22.4%, and 66.2%, respectively, in the 3 groups.
This suggests that the effect of CHF and CRF are addi-
tive in production of the anemia.
There are other causes of anemia in CHF. Angioten-
sin-converting enzyme inhibitors themselves may cause
anemia [45], and these are standard therapy in CHF.
Many CHF patients take aspirin, which may cause blood
loss in the gut. Congestive heart failure patients often
have proteinuria, and both EPO, iron, and transferrin
can be lost in significant amounts in the urine [46], also
contributing to the anemia. The anemia may also be
related to the increased plasma volume, causing hemo-
dilution, but in the majority of cases there is also a re-
duced red cell volume [15].
Sensitivity of the damaged heart to anemia
The failing or ischemic heart may be very sensitive to
even minimal falls in Hb, and anemia may worsen or
precipitate severe CHF and/or ischemia in these patients
at Hb levels that one might generally consider “normal,”
such as 11 g/dL. Certainly, there is much experimental
evidence in animals to support this concept. When the
coronary arteries of these animals were narrowed or
their hearts damaged by other means, CHF developed
at much higher Hb levels than in normal controls [47, 48].
In patients with ischemic heart disease (IHD) who were
operated on but not given transfusions, their 30-day post-
operative risk of mortality or serious morbidity was much
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greater for each level of lower initial Hb than it was in
those with normal hearts (i.e., the IHD patients showed
increased susceptibility to anemia) [49]. Similarly, in a
recent study of elderly patients with an acute myocardial
infarction, their 30-day mortality was inversely related
to the initial Hematocrit (Hct) up to an Hct of 33% [50].
In addition, transfusions in those with initial Hct levels
of 33% or less reduced the mortality rate compared to
those not transfused.
How does anemia cause CHF?
There are many ways in which anemia can cause CHF
and CKI. The lack of oxygen supply to the heart in the
face of the increased heart rate and stroke volume may
cause ischemia and lead to myocardial cell death. The
red blood cells contain many antoxidants, and therefore
anemia is associated with increased oxidative stress
[51, 52] that could cause damage to the myocardial cells.
Treatment of the anemia with EPO can reduce the oxida-
tive stress [51, 52]. There is even some evidence that
EPO alone can reduce oxidative stress independent of
its’ effect on Hb [53].
Anemia causes tissue ischemia throughout the body,
which causes peripheral vasodilatation and a lowering
of the blood pressure [54]. The sympathetic system is
activated, which, in addition to causing tachycardia and
increased stroke volume, also causes renal vasoconstric-
tion, which can lead to salt and water retention. The
reduced renal blood flow activates the renin-angiotensin
aldosterone system (RAAS) and antidiuretic hormone
(ADH), causing further renal vasoconstriction and salt
and water retention. This leads to peripheral edema and
increased plasma volume (PV). The increased PV causes
ventricular dilation, which puts a further stress on the
already stressed heart. Under the influence of the RAAS
and sympathetic activity, left ventricular hypertrophy
(LVH) eventually occurs, which can lead to myocardial
cell death from necrosis and apoptosis [55, 56]. This can
lead to or worsen CHF.
Can EPO alone affect the heart unrelated to its effect
on anemia?
In 2 recent in vitro studies EPO itself could directly
reduce apoptosis in cardiac myocytes exposed to isch-
emia [57, 58]. In in vivo studies in rats [57] and rabbits
[58] it was found that when a myocardial infarction was
produced, the early addition of EPO reduced the size
of the necrotic area and improved cardiac contractility
and function, without any change in Hb. In our own
laboratory (Y Wollman et al, in preparation), we studied
the protective effect of pretreatment with Darbopoeitin
alpha (ARANESP), a erythropoietin-stimulating pro-
tein closely related to erythropoietin, on anoxic-reoxy-
genation (AR)–induced damage inflicted on a culture
of rat cardiac myocytes. Pre-treatment with ARANESP
reversed the AR-induced necrosis of cardiac myocytes
almost to the level of control.
Erythropoietin has also been found in animal studies
to have a direct effect both on the development of cardiac
muscle in utero [59] and on the degree of myocardial
contractility [60].
What is the effect of correction of anemia on the CHF
and the associated CKI?
Regular treatment with EPO in CKI in the predialysis
period in patients who eventually required hemodialysis
significantly reduced the incidence of hospitalization for
CHF in the predialysis period, and in the dialysis period
as well compared to those who received EPO sporadi-
cally or not at all [23]. Thus, it appears that treatment
of anemia in CKD helps prevent CHF.
To assess the importance of this mild anemia in se-
verely symptomatic (NYHA III-IV) CHF patients resis-
tant to maximally tolerated doses of all the CHF medica-
tions, we corrected this anemia in both uncontrolled and
controlled [3–6] studies in a joint nephrology-cardiology
CHF program. We found that when their anemia was
corrected to a Hb level of 12 to 13 g/dL with a combina-
tion of subcutaneous EPO and intravenous (IV) iron
(Venofer), the CHF markedly improved. The patients
had a marked improvement in their shortness of breath
and fatigue as measured by the New York Heart Associa-
tion (NYHA) functional class and by a self-administered
visual analog scale. Their left ventricular ejection frac-
tion (LVEF), [as measured by multiple gated radioactive
angiography (MUGA)] also improved. In addition, the
rate of hospitalization and dose of oral and IV diuretics
fell with the correction of the anemia, and their glomeru-
lar filtration rate (GFR), which had been falling steadily
at a rate of about 1 mL/min/month prior to therapy for
their anemia, stabilized when the anemia was corrected.
In a recent randomized placebo-controlled study of
EPO in severe CHF, the use of EPO was found to im-
prove peak oxygen consumption during exercise, one of
the most sensitive tests of cardiac function, and improved
exercise duration and quality of life (QOL) [61]. This
relationship between Hb level and peak oxygen con-
sumption during exercise in CHF has recently been con-
firmed by others [62].
The role of anemia in CHF in the production of
malnutrition and cardiac cachexia
Patients with CHF and anemia often have signs of
malnutrition, such as a lowered body mass index (BMI),
serum albumin, and cholesterol [19]. In a prospective
study in 9 CRA patients (Vaisman N et al, submitted
for publication), we found that correction of the anemia
over 3 months was associated with a significant increase
in caloric intake, which was reflected by a significant
increase in resting energy expenditure, as measured by
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Table 1. Two year mortality and incidence of ESRD in a random
sample of 1.1 million US Medicare population (Reference 65)
2 year 2 year incidence
mortality % of ESRD %
No anemia, CHF or CKI 7.7 0.1
Anemia 16.6 0.2
CHF 26.1 0.2
CHF and anemia 34.6 0.3
CKI 16.6 2.6
CKI and anemia 27.3 5.4
CHF and CKI 38.4 3.4
CHF and CKI and anemia 45.6 5.9
ESRD is end-stage renal disease.
resting oxygen utilization. Thus, anemia may be respon-
sible for part of the anorexia, weight loss, and cachexia
seen in severe CHF. The defect in energy metabolism
caused by the anemia and the associated tissue hypoxia
(with a switch from aerobic to anaerobic metabolism)
can lead to increased catabolism, wasting, and malnutri-
tion [63]. The essential amino acids are channeled into
energy production instead of into anabolism and cell
growth. This can cause weight loss and malnutrition, and
is reflected in a deficiency of essential amino acids in the
body and reduced levels of essential amino acids in the
blood [63]. Correction of the anemia with EPO and IV
iron eliminates the tissue hypoxia and therefore returns
the metabolism to the normal aerobic and anabolic state,
which is reflected in a return of the plasma essential
amino acid levels to normal and an improved nutritional
state [63].
Use of IV iron as an adjuvant to EPO
In the studies we performed to treat the anemia of
CHF with EPO, we maintained normal iron stores with
IV iron (Venofer) [1–4]. This agent has been shown to
have very few side effects, it increase the Hb even further
than EPO alone, and it allows lower doses of EPO to
be used, thus reducing cost of treatment [64].
The effect of the Cardio Renal Anemia Syndrome on
mortality and ESRD
The above data all suggest that the combination of
CHF, CKI, and anemia seems to have an additive effect
on morbidity and mortality in CHF and CKI. This power-
ful interaction of the 3 is suggested by a recent study of
a 5% sample of the Medicare population in the United
States [65]. The 2-year risk of dying or of starting dialysis
is shown in Table 1. Each of these 3 factors increase the
risk of death or ESRD by 50 to 100% and the 3 together,
increasing the chances by up to 300%. This interaction
between the 3 factors is consistent with the presence of
a vicious circle—the Cardio Renal Anemia Syndrome.
In a study we recently performed on 129 consecutive
patients with CHF (Wexler D et al, submitted for publi-
cation) we measured the beta-type natriuretic peptide
(BNP), which is considered to be one of the best tests
for measuring the severity of CHF [66]. We found that
left ventricular ejection fraction, the serum creatinine,
and the Hb were all independent predictors of the BNP
levels, again strengthening the concept of the additive
effect of all three conditions.
The implications of the Cardio Renal
Anemia Syndrome
The need for earlier and better evaluation of cardiac
damage in every CKI patient. We suggest that, in many
cases of CHF, anemia is a major contributing factor to
progressive CHF and CKI. Both CHF and anemia cause
renal vasoconstriction and renal ischemia, which can lead
to renal fibrosis and progressive renal failure [39]. This
is not to say that diabetes or hypertension is not contrib-
uting to the renal failure directly, but that in many cases
these conditions, in addition to causing direct renal dam-
age, cause cardiac damage and eventual CHF, and that
the CHF itself is a major contributor to the progressive
CKI. In studies we have done in both diabetics and non-
diabetics with CHF [4], aggressive CHF treatment and
treatment of the associated anemia in both groups re-
sulted in a stabilization of renal function, as well as an
improvement in the CHF. Therefore, it is possible that
what is called diabetic nephropathy may, to some extent,
be ischemic nephropathy resulting from uncontrolled
CHF. Thus, it behooves nephrologists to carefully assess
the heart early in every patient with CKI. Cardiac assess-
ment in the routine evaluation of any CKI patient, in
addition to including an EKG and chest x-ray, should
include an echocardiogram. On echocardiogram, many
may have signs of ventricular dilation, LVH, and evi-
dence of systolic and/or diastolic dysfunction, even with-
out clinical evidence of CHF [67].
There is a growing agreement among cardiologists that
routine measurement of B-type natriuretic peptide is
also useful in diagnosing CHF [66]. This peptide is re-
leased from the ventricles in response to increased ven-
tricular volume and pressure, which results in increased
ventricular wall stress. B-type natriuretic peptide has
now been shown to be a very useful adjuvant to the
diagnosis of CHF [66]. It has a high degree of sensitivity,
since about 95% of CHF patients have moderately ele-
vated to very high BNP values (500 pg/mL) [66]. B-type
natriuretic peptide has been shown to have a high speci-
ficity, such that about 85% of patients with moderately
to severely elevated BNP levels (500 pg/mL) have CHF
[66]. Importantly, BNP also has a strong negative pre-
dictive value, such that if the BNP is normal the chances
of the patient having CHF are extremely unlikely. In the
study mentioned earlier we performed BNP measure-
ments on 129 CHF patients seen in our outpatient CHF
clinic. All but 1 had elevated BNP levels (100 pg/mL)
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and the average value was 2888 pg/mL. The BNP test is
relatively inexpensive and takes only a few minutes to
do. It may become a very important test to include in
the diagnostic workup of CKI patients [66]. Since many
CHF patients may not have a clear clinical picture of
CHF, a high BNP would help confirm the diagnosis in
questionable cases, and a normal BNP would almost
certainly rule it out [66].
The need for better medical treatment of CHF. Al-
though nephrologists treating CKI patients are aware of
the benefits of ACE inhibitors in patients with associated
CHD or CHF, they seem to be less aware of the benefits
of beta blockers. In CKI patients, only about 34% of
those with associated CHD are on beta blockers [68],
despite their proven marked cardioprotective effect in
CHF [7, 8] and possible renoprotective effect [37]. In
hemodialysis patients, use of beta blockers was associ-
ated with the greatest reduction in mortality of all the
antihypertensive agents used and were the only agents
that retained this association with lower mortality rates
in comorbidity adjusted models [69]. Furthermore, in
a randomized placebo-controlled study of hemodialysis
patients with severe dilated cardiomyopathy, the use of
carvedilol over 2 years was associated with a lower mor-
tality and rate of hospitalization than the placebo group
[70]. All of this suggests that greater use of beta blockers,
in addition to ACE inhibitors or angiotensin receptor
blockers, should become an important aim in the treat-
ment of CKI patients with evidence of CHF, dilated
cardiomyopathy, or ventricular dysfunction.
The need for a common effort with cardiologists and
other physicians. In our hospital, about 50% of the pa-
tients that we see with the combination of CHF, CKI,
and anemia (i.e., the CRA syndrome) are being sent to
us for treatment of the anemia by cardiologists. This is in
contrast to the findings of the Pre Dialysis Survey on
Anemia Management (PRESAM) survey of 4333 pa-
tients who started dialysis in 779 dialysis centers through-
out the world [71]. In this study, only 3% of all consults
to nephrologists for management of CKI and anemia
come from cardiologists. This means that our patients
with CKI are starting treatment with Hb levels of 11
g/dL and not 8 g/dL as they previously were, with serum
creatinine values of 2 mg/dL and not 5 mg/dL as they
previously were, and with CHF that is not severe and
almost irreversible, as was frequently the case previously.
The close cooperation between nephrologists and cardiolo-
gists has taught us how synergistic such a relationship
can be. The cardiolgists have learned the value of correc-
tion of anemia in CHF and now refer such anemic CHF
patients early. Nephrologists are greatly aided by the
cardiologists’ wide knowledge of CHF. The cardiologists
may discover and treat reversible causes of CHF, such
asynchronous cardiac contraction (which can be cor-
rected with a biventricular pacemaker), or ischemic heart
disease with a hibernating heart, which could respond
to coronary artery bypass graft or angioplasty.
Other major sources of patients with the CRA syn-
drome are medical and geriatric wards where many pa-
tients have CHF and CKI, are anemic, and often are
being hospitalized again and again. Indeed, in a study
of 46,788 consecutive admissions to medical wards, 24%
had CHF [72]. Discussion with the attending physicians
will improve the possibility of early referral to nephrol-
ogy for treatment of their anemia, as well as for other
renal problems. Another major source of CRA may be
diabetic clinics. In a recent study in a diabetic clinic, 23%
of diabetics were found to be anemic [73], the prevalence
and severity being related to the degree of proteinuria
and renal damage.
CONCLUSION
A vicious circle appears to be present in CHF (Fig.
1), in which CHF causes both anemia and CKI. The CKI
causes more anemia. The anemia and CKI act back to
further worsen the CHF, which then further worsens the
anemia and the CKI and so on. We suggest calling this
relationship the Cardio Renal Anemia (CRA) syn-
drome, and we consider it to be very common. The condi-
tion is under-recognized, underdiagnosed, and under-
treated. The importance of the concept of CRA is that
if the anemia is not treated in CHF patients there will
likely be resistant to any other form of CHF therapy,
and there will be progression of the CHF, the CKI, and
the anemia. On the other hand, if the patient does not
get maximal cardioprotective medications, the CHF and
CKI will progress, even if the anemia is treated. Thus,
both correction of anemia and the adequate detection
and treatment of CHF are crucial in stabilizing or im-
proving both the CHF and the CKI. The management
of the CRA syndrome will involve interdisciplinary co-
operation between nephrologists, cardiologists, diabetol-
ogists, other internists, and family physicians.
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